BCM
KROS icon

Bayesian Capital Management’s Keros Therapeutics KROS Stock Holding History

Bayesian Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,029
Closed -$267K – 928
2024
Q1 		$267K Buy
+4,029
New +$239K 0.03% 588

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Bayesian Capital Management's KROS Position: Q2 2024 in Review

Bayesian Capital Management sold out of Keros Therapeutics (KROS) in Q2 2024, closing a stake of 4,029 shares — an estimated $267K sold.

Bayesian Capital Management first reported a position in KROS in Q1 2024 and held it in 1 quarter. The position peaked at $267K in Q1 2024. 152 funds tracked by Wall St. Rank hold KROS as of Q2 2024.

  • Bayesian Capital Management reported no remaining Keros Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 4,029 Keros Therapeutics shares in Q2 2024, an estimated $267K.
  • Bayesian Capital Management first reported a position in Keros Therapeutics in Q1 2024 and held it in 1 quarter.
  • Bayesian Capital Management's Keros Therapeutics position peaked at $267K in Q1 2024.
  • 152 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.